A study of tranexamic acid to reduce blood loss during hip surgery in children with hip dysplasia and other hip conditions

3 1 1

What is this study about?

This study focuses on several conditions affecting the hip in children, including Slipped Capital Femoral Epiphysis, Legg-Calvé-Perthes Disease, and Developmental Dysplasia of the Hip. These conditions may require surgical procedures involving the hip bone. During such operations, blood loss can occur, which is what this study aims to address.

The study will test whether a medication called tranexamic acid can help reduce the amount of blood lost during hip surgery in children. Some patients will receive tranexamic acid through an injection into their vein, while others will receive a placebo with saline solution. The medication or placebo will be given before the surgery starts.

The surgical procedures involved in this study are proximal femoral osteotomy and pelvic osteotomy, which are operations where surgeons make controlled cuts in the hip bones to improve their position and function. During the study, doctors will measure how much blood is lost during surgery and monitor the patients’ recovery. This will help determine if tranexamic acid is effective in reducing blood loss during these types of hip surgeries in children.

1 Initial treatment preparation

Your participation begins with preparation for hip surgery. This surgery is called proximal femoral and/or pelvic osteotomy, which means making controlled cuts in the hip bone to improve its position.

Before the surgery, you will be randomly assigned to receive either tranexamic acid (a medication that helps control bleeding) or saline (salt water solution) through an intravenous injection.

2 Pre-operative procedures

Medical staff will take blood samples to measure your baseline blood values, including hemoglobin (a protein that carries oxygen in your blood).

The medical team will record your basic health information and medical history, including any previous surgeries in the same area.

3 Surgery day

You will receive the assigned medication (either tranexamic acid or saline) through an intravenous line before the surgery begins.

During the surgery, the medical team will monitor and record the amount of blood loss.

If needed, additional medications to control bleeding may be administered during the procedure.

4 Post-operative monitoring

After surgery, medical staff will take blood samples to check your blood values again.

The medical team will monitor for any complications and record if any blood transfusions are needed.

Your hospital stay duration will be documented as part of the study data.

5 Study completion

The study concludes after your hospital discharge and final blood tests.

All collected data will be used to evaluate how effective tranexamic acid is in reducing blood loss during hip surgery.

Who Can Join the Study?

  • Patient must be between 1 and 18 years old
  • Patient must need a hip bone surgery that involves either:
    • Surgery of the upper part of the thigh bone (proximal femoral osteotomy), or
    • Surgery of the hip socket (pelvic osteotomy), or
    • Both types of surgery together
  • The surgery can be needed for any medical reason, including:
    • Slipped growth plate in the hip
    • Hip joint development problems
    • Muscle and nerve conditions affecting the hip
  • Both male and female patients can participate
  • Patient must be scheduled for surgery at the study hospital
  • Patient’s parent or legal guardian must agree to participation if the patient is under the age of consent

Who Cannot Join the Study?

  • Patients with a history of blood clotting disorders (conditions that affect how blood forms clots)
  • Those currently taking anticoagulation medications (blood-thinning drugs)
  • Known allergic reactions to tranexamic acid (TXA) or similar medications
  • Active bleeding disorders or significant bleeding risks
  • Severe kidney problems (as TXA is cleared through the kidneys)
  • History of seizures or epilepsy
  • Current urinary tract bleeding
  • Patients with color vision deficiency (as this may affect monitoring)
  • Those who received blood transfusions within the last 3 months
  • Children with severe liver disease
  • Patients with uncontrolled high blood pressure
  • Those participating in other clinical trials
  • Inability to comply with study follow-up requirements
  • Lack of parent/guardian consent for study participation

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Emzkoyj Ugchlnvoupro Mbrbybf Ckhxxwj Rthxhgini (lxylmjv Mjt Rotterdam The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Recruiting
17.04.2023

Trial locations

Investigated drugs:

Tranexamic acid (TXA) is a medication that helps reduce bleeding during surgery. It works by preventing blood clots from breaking down too quickly, which helps control blood loss. This medication is given before surgery and is particularly useful in orthopedic procedures like hip surgeries. It’s a well-established medication that has been used safely in both adults and children to manage surgical bleeding.

Placebo is an inactive substance that contains no medication. It’s used as a comparison to measure how effective the real medication (tranexamic acid) is at reducing blood loss during surgery.

Investigated diseases:

Slipped capital femoral epiphysis (SCFE) – A hip condition where the upper end of the thigh bone (femoral head) slips backward off the neck of the bone. This condition typically occurs during periods of rapid growth in adolescence. The slip develops gradually over time and can affect one or both hips.

Legg-Calvé-Perthes Disease (LCPD) – A childhood hip disorder that affects the head of the femur. The condition occurs when blood supply to the hip joint is temporarily interrupted, causing the bone cells to die. Over time, the bone gradually reforms, but may heal in an abnormal shape.

Neuromuscular conditions – A group of disorders that affect the functioning of muscles and their control by the nervous system. These conditions can cause muscle weakness, movement problems, and impair normal joint development. The conditions can affect various parts of the body including the hips.

Secondary hip dysplasia – A condition where the hip joint develops abnormally as a result of another underlying medical condition or previous trauma. The hip socket may be too shallow or incorrectly shaped, leading to improper fit of the hip joint.

Developmental dysplasia of the hip (DDH) – A condition present from birth where the hip joint hasn’t formed normally. The ball part of the joint may be loose in the socket or may be completely dislocated. This condition can affect one or both hips and ranges from mild to severe.

Trial ID:
2024-516324-34-01
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on Tranexamic Acid Oral Solution for Preventing Bleeding in Patients on Blood Thinners Undergoing Tooth Extraction

    Recruiting

    3 1
    Investigated drugs:
    Croatia Hungary Romania Spain